keyword
https://read.qxmd.com/read/34284431/statin-therapy-in-midlife-women
#21
JOURNAL ARTICLE
Chrisandra L Shufelt
The menopause transition is associated with adverse changes to the lipid profile. Although there are no specific treatment guidelines for women, current evidence supports the use of statin therapy in women with 1) established clinical atherosclerotic cardiovascular disease (ASCVD); 2) primary hypercholesterolemia, with low-density lipoprotein cholesterol of 190 mg/dL (4.9 mmol/L) or higher; 3) diabetes mellitus regardless of ASCVD risk category (ages 40-75 y); and 4) for primary prevention of ASCVD in women at high risk (10-y risk, ≥20%) or intermediate risk (10-y risk, ≥7...
July 19, 2021: Menopause: the Journal of the North American Menopause Society
https://read.qxmd.com/read/34162218/pravastatin-versus-placebo-in-pregnancies-at-high-risk-of-term-preeclampsia
#22
RANDOMIZED CONTROLLED TRIAL
Moritz Döbert, Anna Nektaria Varouxaki, An Chi Mu, Argyro Syngelaki, Anca Ciobanu, Ranjit Akolekar, Catalina De Paco Matallana, Simona Cicero, Elena Greco, Mandeep Singh, Deepa Janga, Maria Del Mar Gil, Jacques C Jani, José Luis Bartha, Kate Maclagan, David Wright, Kypros H Nicolaides
BACKGROUND: Effective screening for term preeclampsia is provided by a combination of maternal factors with measurements of mean arterial pressure, serum placental growth factor, and serum soluble fms-like tyrosine kinase-1 at 35 to 37 weeks of gestation, with a detection rate of ≈75% at a screen-positive rate of 10%. However, there is no known intervention to reduce the incidence of the disease. METHODS: In this multicenter, double-blind, placebo-controlled trial, we randomly assigned 1120 women with singleton pregnancies at high risk of term preeclampsia to receive pravastatin at a dose of 20 mg/d or placebo from 35 to 37 weeks of gestation until delivery or 41 weeks...
August 31, 2021: Circulation
https://read.qxmd.com/read/33771965/minimal-change-disease-after-elective-surgical-abortion-a-case-report
#23
JOURNAL ARTICLE
Sheldon Greenberg, Kundan R Jana, Kalyana C Janga, Kamlesh Kumar
BACKGROUND Pregnancy causes a physiological increase in renal blood flow and glomerular filtration rate, which leads to a transient increase in urinary protein excretion. Up to 300 mg/d proteinuria is known to occur in pregnancy due to physiological changes. Proteinuria of greater than 3 g/d is categorized as being within the nephrotic range, and the most common cause of nephrotic range proteinuria in the later stages of pregnancy is preeclampsia. Minimal change disease (MCD) as a cause of nephrotic syndrome is rare in pregnancy and is rarer still after abortion...
March 27, 2021: American Journal of Case Reports
https://read.qxmd.com/read/33771361/the-placenta-and-preeclampsia-villain-or-victim
#24
REVIEW
Karen Melchiorre, Veronica Giorgione, Basky Thilaganathan
Preeclampsia is a disease whose characterization has not changed in the 150 years since the cluster of signs associated with the disorder were first described. Although our understanding of the pathophysiology of preeclampsia has advanced considerably since then, there is still little consensus regarding the true etiology of preeclampsia. As a consequence, preeclampsia has earned the moniker "disease of theories," predominantly because the underlying biological mechanisms linking clinical epidemiologic findings to observed organ dysfunction in preeclampsia are far from clear...
February 2022: American Journal of Obstetrics and Gynecology
https://read.qxmd.com/read/33419165/pravastatin-promotes-endothelial-colony-forming-cell-function-angiogenic-signaling-and-protein-expression-in-vitro
#25
JOURNAL ARTICLE
Nadia Meyer, Lars Brodowski, Katja Richter, Constantin S von Kaisenberg, Bianca Schröder-Heurich, Frauke von Versen-Höynck
Endothelial dysfunction is a primary feature of several cardiovascular diseases. Endothelial colony-forming cells (ECFCs) represent a highly proliferative subtype of endothelial progenitor cells (EPCs), which are involved in neovascularization and vascular repair. Statins are known to improve the outcome of cardiovascular diseases via pleiotropic effects. We hypothesized that treatment with the 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitor pravastatin increases ECFCs' functional capacities and regulates the expression of proteins which modulate endothelial health in a favourable manner...
January 6, 2021: Journal of Clinical Medicine
https://read.qxmd.com/read/33333432/effects-of-statins-on-preeclampsia-a-systematic-review
#26
JOURNAL ARTICLE
Amir Vahedian-Azimi, Leila Karimi, Željko Reiner, Somayeh Makvandi, Amirhossein Sahebkar
BACKGROUND: Preeclampsia is a serious complication of pregnancy which increases the morbidity and mortality of both the fetus and pregnant woman. It is characterized by imbalances in angiogenesis, inflammation and endothelial dysfunction which cause the development of hypertension and proteinuria, sometimes progressing into a multisystem disorder. The aim of this systematic review was to analyze all the available data on statins and preeclampsia. METHOD: MEDLINE/PubMed, OVID, EMBASE, Web of Sciences, and SCOPUS were searched from inception to May 5, 2020...
March 2021: Pregnancy Hypertension
https://read.qxmd.com/read/33238177/nuclear-magnetic-resonance-based-metabolomic-analysis-in-the-assessment-of-preclinical-atherosclerosis-in-type-1-diabetes-and-preeclampsia
#27
JOURNAL ARTICLE
Antonio J Amor, Irene Vinagre, Maite Valverde, Xavier Urquizu, Eva Meler, Eva López, Nuria Alonso, Adriana Pané, Marga Giménez, Laura Codina, Ignacio Conget, Maria J Barahona, Verónica Perea
AIMS: Evaluate the role of plasma metabolomics in atherosclerosis according to the presence of type 1 diabetes (T1D) or previous preeclampsia. METHODS: We recruited 105 women without cardiovascular disease and last pregnancy ≥5 years previously, divided according to the presence of T1D or previous preeclampsia. Preclinical atherosclerosis was defined as the presence of carotid plaque (intima-media thickness ≥1.5 mm) assessed by ultrasonography. Metabolomics were evaluated by nuclear magnetic resonance (NMR)...
January 2021: Diabetes Research and Clinical Practice
https://read.qxmd.com/read/32980138/novel-approaches-to-combat-preeclampsia-from-new-drugs-to-innovative-delivery
#28
REVIEW
Natasha de Alwis, Natalie K Binder, Sally Beard, Tu'uhevaha J Kaitu'u-Lino, Stephen Tong, Fiona Brownfoot, Natalie J Hannan
Preeclampsia is a complex disease affecting 2-8% of pregnancies worldwide. It poses significant risk of maternal and perinatal morbidity and mortality. Despite the rising research interest to discover new therapeutic approaches to prevent and treat preeclampsia, options remain limited. Identifying the important pathological stages in the progression of this disease allows us to evaluate effective candidate therapeutics. Three important stages in the pathophysiology are: 1) placental hypoxia and oxidative stress, 2) excess release of anti-angiogenic and pro-inflammatory factors, and 3) widespread systemic endothelial dysfunction and vasoconstriction...
December 2020: Placenta
https://read.qxmd.com/read/32818477/the-role-of-statins-in-the-prevention-of-preeclampsia
#29
REVIEW
Devin D Smith, Maged M Costantine
Preeclampsia is a common hypertensive disorder of pregnancy associated with considerable neonatal and maternal morbidities and mortalities. However, the exact cause of preeclampsia remains unknown; it is generally accepted that abnormal placentation resulting in the release of soluble antiangiogenic factors, coupled with increased oxidative stress and inflammation, leads to systemic endothelial dysfunction and the clinical manifestations of the disease. Statins have been found to correct similar pathophysiological pathways that underlie the development of preeclampsia...
February 2022: American Journal of Obstetrics and Gynecology
https://read.qxmd.com/read/32515046/nuclear-magnetic-resonance-lipoproteins-are-associated-with-carotid-atherosclerosis-in-type-1-diabetes-and-pre-eclampsia
#30
JOURNAL ARTICLE
Antonio J Amor, Irene Vinagre, Maite Valverde, Xavier Urquizu, Eva Meler, Eva López, Carmen Quirós, Marga Giménez, Laura Codina, Ignacio Conget, Maria J Barahona, Verónica Perea
AIMS: Persistence of lipoprotein abnormalities in type 1 diabetes (T1D) and/or pre-eclampsia could be associated with cardiovascular disease (CVD). We assessed differences in the advanced lipoprotein profiles according to the presence of both conditions and their differential association with atherosclerosis. MATERIAL AND METHODS: We recruited 112 women without CVD and last pregnancy ≥5 years previously, divided into four groups (n = 28 per group): (a) T1D and previous pre-eclampsia; (b) T1D without pre-eclampsia; (c) pre-eclampsia without T1D; and (d) controls (without T1D/pre-eclampsia)...
January 2021: Diabetes/metabolism Research and Reviews
https://read.qxmd.com/read/32485787/pravastatin-for-preeclampsia-from-animal-to-human
#31
JOURNAL ARTICLE
Keiichi Kumasawa, Takayuki Iriyama, Takeshi Nagamatsu, Yutaka Osuga, Tomoyuki Fujii
Preeclampsia is characterized by the emergence of hypertension and proteinuria after 20 weeks of pregnancy, and it threatens both maternal and fetal lives if it proceeds unabated. Despite numerous studies, thus far the only fundamental therapy for preeclampsia is termination of pregnancy, leading to preterm birth. Furthermore, preeclamptic women are reported to be at risk for cardiovascular diseases for 10 years after delivery. Therefore, preventative and therapeutic strategies for preeclampsia are required...
August 2020: Journal of Obstetrics and Gynaecology Research
https://read.qxmd.com/read/32220554/tracking-the-development-of-cerebrovascular-risk-factors-following-pregnancy-with-preeclampsia
#32
JOURNAL ARTICLE
Madeline Lederer, Adriana Wong, Daniela Diego, Desiree Nguyen, Usha Verma, Seemant Chaturvedi
OBJECTIVE: To evaluate the development and management of cerebrovascular risk factors following a pregnancy with preeclampsia. METHODS: This is a retrospective chart review including women diagnosed with preeclampsia between 2012 and 2013 with later encounters within 2014-2016. For each subject that met inclusion criteria, the development of cerebrovascular risk factors was determined using ICD codes within the 2014-2016 electronic medical record (EMR). For subjects who developed risk factors, current treatment was determined from the EMR...
March 24, 2020: Journal of Stroke and Cerebrovascular Diseases: the Official Journal of National Stroke Association
https://read.qxmd.com/read/32052203/novel-interventions-for-the-prevention-of-preeclampsia
#33
REVIEW
Marwan Ma'ayeh, Kara M Rood, Douglas Kniss, Maged M Costantine
PURPOSE OF REVIEW: To review the rationale and biological plausibility and discuss the current research on novel interventions for the prevention of preeclampsia. RECENT FINDINGS: Preeclampsia affects up to 8% of pregnancies worldwide and remains a major cause of maternal and neonatal morbidity and mortality. Multiple medications have been investigated or repurposed as potential effective interventions for preeclampsia prevention. Aspirin is currently the only drug for which there is some evidence of benefit for preeclampsia prevention, and its use is recommended by professional societies for pregnancies at risk...
February 12, 2020: Current Hypertension Reports
https://read.qxmd.com/read/31869519/pravastatin-to-ameliorate-early-onset-pre-eclampsia-promising-but-not-there-yet
#34
COMMENT
M M Costantine
No abstract text is available yet for this article.
March 2020: BJOG: An International Journal of Obstetrics and Gynaecology
https://read.qxmd.com/read/31786987/statins-reverse-postpartum-cardiovascular-dysfunction-in-a-rat-model-of-preeclampsia
#35
JOURNAL ARTICLE
Kristin Kräker, Jamie M O'Driscoll, Till Schütte, Florian Herse, Olga Patey, Michaela Golic, Sabrina Geisberger, Stefan Verlohren, Anna Birukov, Arnd Heuser, Dominik N Müller, Basky Thilaganathan, Ralf Dechend, Nadine Haase
Preeclampsia is associated with increased cardiovascular long-term risk; however, the underlying functional and structural mechanisms are unknown. We investigated maternal cardiac alterations after preeclampsia. Female rats harboring the human angiotensinogen gene [TGR(hAogen)L1623] develop a preeclamptic phenotype with hypertension and albuminuria during pregnancy when mated with male rats bearing the human renin gene [TGR(hRen)L10J] but behave physiologically normal before and after pregnancy. Furthermore, rats were treated with pravastatin...
January 2020: Hypertension
https://read.qxmd.com/read/31715077/pravastatin-for-early-onset-pre-eclampsia-a-randomised-blinded-placebo-controlled-trial
#36
RANDOMIZED CONTROLLED TRIAL
A Ahmed, D J Williams, V Cheed, L J Middleton, S Ahmad, K Wang, A T Vince, P Hewett, K Spencer, K S Khan, J P Daniels
OBJECTIVE: Women with pre-eclampsia have elevated circulating levels of soluble fms-like tyrosine kinase-1 (sFlt-1). Statins can reduce sFlt-1 from cultured cells and improve pregnancy outcome in animals with a pre-eclampsia-like syndrome. We investigated the effect of pravastatin on plasma sFlt-1 levels during pre-eclampsia. DESIGN: Blinded (clinician and participant), proof of principle, placebo-controlled trial. SETTING: Fifteen UK maternity units...
March 2020: BJOG: An International Journal of Obstetrics and Gynaecology
https://read.qxmd.com/read/31529047/preeclampsia-is-associated-with-increased-preclinical-carotid-atherosclerosis-in-women-with-type-1-diabetes
#37
JOURNAL ARTICLE
Antonio J Amor, Irene Vinagre, Maite Valverde, Adriana Pané, Xavier Urquizu, Eva Meler, Eva López, Carmen Quirós, Marga Giménez, Laura Codina, Ignacio Conget, Maria J Barahona, Verónica Perea
PURPOSE: Although preeclampsia is a well-established cardiovascular risk factor (CVRF) in the general population, its role in type 1 diabetes (T1D) has been scarcely studied. We assessed the association between preeclampsia and preclinical atherosclerosis in T1D. METHODS: We recruited 112 women without cardiovascular disease and last pregnancy ≥5 years before: a) T1D and previous preeclampsia (T1D+/PE+; n=28); b) T1D without preeclampsia (T1D+/PE-; n=28); c) Previous preeclampsia without T1D (T1D-/PE+; n=28); and d) Controls (without T1D or preeclampsia; T1D-/PE-; n=28)...
September 16, 2019: Journal of Clinical Endocrinology and Metabolism
https://read.qxmd.com/read/30712660/pravastatin-improves-fetal-survival-in-mice-with-a-partial-deficiency-of-heme-oxygenase-1
#38
JOURNAL ARTICLE
Abraham Tsur, Flora Kalish, Jordan Burgess, Nihar R Nayak, Hui Zhao, Kerriann M Casey, Maurice L Druzin, Ronald J Wong, David K Stevenson
INTRODUCTION: Statins induce heme oxygenase-1 (HO-1) expression in vitro and in vivo. Low HO-1 expression is associated with pregnancy complications, e.g. preeclampsia and recurrent miscarriages. Here, we investigated the effects of pravastatin on HO-1 expression, placental development, and fetal survival in mice with a partial HO-1 deficiency. METHODS: At E14.5, untreated pregnant wild-type (WT, n=13-18), untreated HO-1+/- (Het, n=6-9), and Het mice treated with pravastatin (Het+Pravastatin, n=12-14) were sacrificed...
January 2019: Placenta
https://read.qxmd.com/read/30636550/egfr-epidermal-growth-factor-receptor-signaling-and-the-mitochondria-regulate-sflt-1-soluble-fms-like-tyrosine-kinase-1-secretion
#39
JOURNAL ARTICLE
Roxanne Hastie, Fiona C Brownfoot, Natasha Pritchard, Natalie J Hannan, Ping Cannon, Vi Nguyen, Kirsten Palmer, Sally Beard, Stephen Tong, Tu'uhevaha J Kaitu'u-Lino
Preeclampsia is a hypertensive disorder of pregnancy characterized by maternal endothelial dysfunction and end-organ damage. The antiangiogenic factor, sFlt-1 (soluble FMS-like tyrosine kinase-1) has been strongly implicated in the pathogenesis of preeclampsia. sFlt-1 is secreted into the maternal circulation where it antagonizes VEGF (vascular endothelial growth factor) and ultimately disrupts vascular homeostasis. However, the upstream mechanisms regulating release of sFlt-1 are poorly characterized. We investigated the roles of key prosurvival pathways, EGFR (epidermal growth factor receptor) signaling, and the mitochondria, in regulating sFlt-1 production...
March 2019: Hypertension
https://read.qxmd.com/read/30084810/role-of-statin-as-inducer-of-hmox-1-system-in-treatment-of-preeclampsia
#40
REVIEW
Ridwan A Putra, Jusuf S Effendi, Wiryawan Permadi, Ria Bandiara, Prima N Fauziah
Preeclampsia is the major cause of both maternal and neonatal morbidity and mortality. Its insidence remains high and the management has not been established yet because its etiology and pathophysiological are still poorly understood. Theories regarding etiopathogenesis and management of preeclampsia have been postulated yet it remains controversial. Placental ischemic and angiogenic imbalance are suggested to be predisposing factors of preeclampsia. It is thereby targeted in prevention of preeclampsia. Unfortunately, both primary and secondary prevention using various supplements and drugs fails to exhibit good outcome...
July 30, 2018: Cellular and Molecular Biology
keyword
keyword
160999
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.